stockportfolio.pro
Stocks / MDLN vs REGN
MDLN vs REGN
Medline Inc. and Regeneron Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Medline Inc. (MDLN) | Regeneron Pharmaceuticals, Inc. (REGN) | |
|---|---|---|
| Market cap | $64.5B | $64.6B |
| Revenue (latest FY) | $28.43B | $14.34B |
| Net income (latest FY) | $1.16B | $4.50B |
| Revenue growth (5y CAGR) | 7.0% | 11.0% |
| Net margin | 4.1% | 31.4% |
| Return on equity | 10.8% | 14.4% |
| P/E ratio | 31.8 | 15.0 |
| Dividend yield | — | 0.6% |
| Profitable years (of last 10) | 4 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MDLN — free Open REGN — freeFrequently asked questions
Which is bigger, MDLN or REGN?
Regeneron Pharmaceuticals, Inc. is larger by market capitalization — $64.6B versus $64.5B.
Which grows faster, MDLN or REGN?
Over the last five fiscal years, Regeneron Pharmaceuticals, Inc. grew revenue faster — 11.0%/yr versus 7.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.